Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Antiviral Activity of Multiple Doses of HH-006 Injection in Untreated Chronic Hepatitis B Virus Infected Individuals
Conditions
Interventions
HH-006
0.9% normal saline
Locations
3
China
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The Eighth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
December 20, 2024
Primary Completion Date
December 15, 2025
Completion Date
December 15, 2025
Last Updated
April 7, 2026
NCT06537414
NCT06491563
NCT06159062
NCT01708889
Lead Sponsor
Huahui Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions